Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 7Terminated 3Unknown 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 1

Conditions

Upper Tract Urothelial Carcinomas 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Drug Evaluation × Clear all
NCT05682170 2024-09-19

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1/2 Terminated
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

NCT04840784 2023-10-11

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Terminated
9 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡